



| | | | |
|---------------------|--|------------------------|--|
| PATIENT INFORMATION | Patient Name: _____ | PRESCRIBER INFORMATION | Prescriber's Name: _____ |
| | Address: _____ | | State License #: _____ NPI #: _____ |
| | City: _____ State: _____ Zip: _____ | | DEA #: _____ |
| | Primary Phone: _____ DOB: _____ | | Group or Hospital: _____ |
| | Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female | | Address: _____ |
| | E-mail: _____ | | City, State Zip: _____ State: _____ Zip: _____ |
| | Primary Language: _____ | | Phone: _____ Fax: _____ |
| | Height: _____ Weight: _____ | | Contact Person: _____ Phone: _____ |

INSURANCE INFORMATION: PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)

| | | |
|-------------------------|--|--|
| CLINICAL | Need By Date: _____ | Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Other: |
| | Date of Diagnosis: _____ | <input type="checkbox"/> Clinically Isolated Syndrome <input type="checkbox"/> Relapsing-Remitting <input type="checkbox"/> Secondary Progressive <input type="checkbox"/> Primary Progressive |
| | Diagnosis: G35 Multiple Sclerosis | <input type="checkbox"/> Other (ICD-10 Code): _____ |
| | Previous Disease-Modifying Therapy: _____ | |
| | Current Medications: _____ | |
| Allergies: _____ | | Is the patient new to therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No |

| PRESCRIPTION INFORMATION | MEDICATION | DOSE/STRENGTH | DIRECTIONS | QUANTITY | REFILLS |
|--------------------------|--|--|---|--|---------|
| | <input type="checkbox"/> Aubagio | <input type="checkbox"/> 7mg <input type="checkbox"/> 14mg | <input type="checkbox"/> Take 1 tab PO daily. | <input type="checkbox"/> 30 | _____ |
| | <input type="checkbox"/> Avonex PFS <input type="checkbox"/> Avonex Pen | <input type="checkbox"/> 30mcg | <input type="checkbox"/> Titration Dosing (PFS): Week 1: Inject 7.5mcg IM. Week 2: Inject 15mcg IM. Week 3: Inject 22.5mcg IM. Week 4: Start injecting 30mcg IM once a week. <input type="checkbox"/> Inject 30mcg IM once a week. | <input type="checkbox"/> 1 Kit = 4 PFS <input type="checkbox"/> 1 Kit = 4 Pens | _____ |
| | <input type="checkbox"/> Betaseron | <input type="checkbox"/> 0.3mg | <input type="checkbox"/> Titration Dosing: Weeks 1-2: Inject 0.0625mg (0.25mL) SQ QOD Weeks 3-4: Inject 0.125mg (0.5mL) SQ QOD. Weeks 5-6: Inject 0.1875mg (0.75mL) SQ QOD. Week 7: Start injecting 0.25mg (1mL) SQ QOD. <input type="checkbox"/> Inject 0.25mg (1mL) SQ every other day. | <input type="checkbox"/> 1 Kit = 14 devices | _____ |
| | <input type="checkbox"/> Copaxone PFS <input type="checkbox"/> Glatopa PFS <input type="checkbox"/> Glatiramer acetate PFS | <input type="checkbox"/> 20mg <input type="checkbox"/> 40mg | <input type="checkbox"/> Inject 20mg SQ daily. <input type="checkbox"/> Inject 40mg SQ 3 times a week. <input type="checkbox"/> Other | <input type="checkbox"/> 1 Kit = 30 PFS <input type="checkbox"/> 1 Kit = 12 PFS | _____ |
| | <input type="checkbox"/> Dalfampridine | <input type="checkbox"/> 10mg tab | <input type="checkbox"/> Take 1 tablet PO twice daily approximately 12 hours apart. | <input type="checkbox"/> 60 | _____ |
| | <input type="checkbox"/> Extavia | <input type="checkbox"/> 0.3mg | <input type="checkbox"/> Titration Dosing: Weeks 1-2: Inject 0.0625mg (0.25mL) SQ QOD. Weeks 3-4: Inject 0.125mg (0.5mL) SQ QOD. Weeks 5-6: Inject 0.1875mg (0.75mL) SQ QOD. Week 7: Start injecting 0.25mg (1mL) SQ QOD. <input type="checkbox"/> Inject 0.25mg (1mL) SQ every other day. | <input type="checkbox"/> 1 kit = 15 devices | _____ |
| | <input type="checkbox"/> Gilenya | <input type="checkbox"/> 0.5mg Cap | <input type="checkbox"/> Take 1 cap PO daily. | <input type="checkbox"/> 30 | _____ |
| | <input type="checkbox"/> Mayzent | CYP2C9 Genotype *1/*1, *1/*2, and *2/*2 | <input type="checkbox"/> Titration Dosing: Please contact manufacturer (Alongside MS) | NA | NA |
| | | <input type="checkbox"/> 2mg tab | <input type="checkbox"/> Take 2mg PO daily. | <input type="checkbox"/> 30 | _____ |
| | | CYP2C9 Genotype *1/*3 or *2/*3 | <input type="checkbox"/> Titration Dosing (commercially insured): Please contact manufacturer (Alongside MS) <input type="checkbox"/> Titration Dosing (government insured): 0.25mg PO day 1-2, 0.50mg day 3, 0.75mg day 4, followed by 1mg daily thereafter. <input type="checkbox"/> Take 1mg PO daily. | NA | NA |
| | <input type="checkbox"/> 0.25mg tab | | | <input type="checkbox"/> 112 | _____ |

PHYSICIAN SIGNATURE REQUIRED

x _____
DISPENSE AS WRITTEN (Date)
Ancillary supplies and kits provided as needed for administration
x _____
PRODUCT SUBSTITUTION PERMITTED (Date)

Date Needed: _____ Medication Start Date: _____

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 0124 (5/20)



| | | | |
|----------------------------|--|-------------------------------|--|
| PATIENT INFORMATION | Patient Name: _____ | PRESCRIBER INFORMATION | Prescriber's Name: _____ |
| | Address: _____ | | State License #: _____ NPI #: _____ |
| | City: _____ State: _____ Zip: _____ | | DEA #: _____ |
| | Primary Phone: _____ DOB: _____ | | Group or Hospital: _____ |
| | Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female | | Address: _____ |
| | E-mail: _____ | | City, State Zip: _____ State: _____ Zip: _____ |
| | Primary Language: _____ | | Phone: _____ Fax: _____ |
| | Height: _____ Weight: _____ | | Contact Person: _____ Phone: _____ |

INSURANCE INFORMATION: PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)

| | | | |
|------------------|---|--|-------------------------------------|
| CLINICAL | Need By Date: _____ | Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Other: | |
| | Date of Diagnosis: _____ | <input type="checkbox"/> Clinically Isolated Syndrome <input type="checkbox"/> Relapsing-Remitting <input type="checkbox"/> Secondary Progressive <input type="checkbox"/> Primary Progressive | Number of Relapses Last Year: _____ |
| | Diagnosis: G35 Multiple Sclerosis | <input type="checkbox"/> Other (ICD-10 Code): _____ | |
| | Previous Disease-Modifying Therapy: _____ | | |
| | Current Medications: _____ | | |
| Allergies: _____ | | Is the patient new to therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No | |

| | MEDICATION | DOSE/STRENGTH | DIRECTIONS | QUANTITY | REFILL |
|---------------------------------|--|--|--|---|--------|
| PRESCRIPTION INFORMATION | <input type="checkbox"/> Ocrevus | <input type="checkbox"/> 300mg/10mL | <input type="checkbox"/> Initial Dose: Infuse 300mg IV on day 1, followed by 300mg IV 2 weeks later. <input type="checkbox"/> Maintenance Dose: Infuse 600mg IV every 6 months. | <input type="checkbox"/> 2 SDV | _____ |
| | <input type="checkbox"/> Plegridy PFS <input type="checkbox"/> Plegridy Autoinjector | <input type="checkbox"/> Titration Pack <input type="checkbox"/> 125mcg/0.5mL | <input type="checkbox"/> Titration Dose: Inject 63mcg SQ on day 1, 94mcg on day 15, 125mcg on day 29 and every 14 days thereafter. <input type="checkbox"/> Inject 125mcg SQ every 14 days. | <input type="checkbox"/> 1 Titration Kit = 2 Pen/PFS <input type="checkbox"/> 2 | _____ |
| | <input type="checkbox"/> Rebif PFS <input type="checkbox"/> Rebif Rebidose Autoinjector | <input type="checkbox"/> Titration Pack | <input type="checkbox"/> Titration to 22 mcg dose (PFS only): Weeks 1-2: Inject 4.4mcg SQ 3 times a week. Weeks 3-4: Inject 11mcg SQ 3 times a week. Week 5: Start injecting 22mcg SQ 3 times a week. <input type="checkbox"/> Titration to 44mcg dose: Weeks 1-2: Inject 8.8mcg SQ 3 times a week. Weeks 3-4: Inject 22mcg SQ 3 times a week. Week 5: Start injecting 44mcg SQ 3 times a week. | <input type="checkbox"/> 1 Titration Kit = six 8.8mcg + six 22mcg Syringes or Autoinjectors | 0 |
| | <input type="checkbox"/> Rebif PFS <input type="checkbox"/> Rebif Rebidose Autoinjector | <input type="checkbox"/> 22mcg <input type="checkbox"/> 44mcg | <input type="checkbox"/> Inject 22mcg SQ 3 times a week. <input type="checkbox"/> Inject 44mcg SQ 3 times a week. <input type="checkbox"/> Other | <input type="checkbox"/> 12 | _____ |
| | <input type="checkbox"/> Tecfidera | <input type="checkbox"/> Starter Kit <input type="checkbox"/> 120mg DR cap (dispensed in multiples of #14) <input type="checkbox"/> 240mg DR cap | <input type="checkbox"/> Titration Dose: Take 120mg PO twice daily for 7 days, then take 240mg twice daily thereafter. <input type="checkbox"/> Take 240mg PO twice daily. <input type="checkbox"/> Other | <input type="checkbox"/> 1 Starter Kit (60 caps) <input type="checkbox"/> 60 <input type="checkbox"/> Other _____ | _____ |
| | <input type="checkbox"/> Vumerity | <input type="checkbox"/> Starter Kit <input type="checkbox"/> 231 mg DR cap | <input type="checkbox"/> Titration Dose: Take 231mg PO twice daily for 7 days, then take 462mg twice daily thereafter. <input type="checkbox"/> Take 462mg PO twice daily. <input type="checkbox"/> Other | <input type="checkbox"/> 1 Starter Kit (106 caps) <input type="checkbox"/> 120 | _____ |

PHYSICIAN SIGNATURE REQUIRED

x _____ (Date)
DISPENSE AS WRITTEN
Ancillary supplies and kits provided as needed for administration
x _____ (Date)
PRODUCT SUBSTITUTION PERMITTED

Date Needed: _____ Medication Start Date: _____

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 0124 (7/20)



| | | | |
|----------------------------|--|-------------------------------|--|
| PATIENT INFORMATION | Patient Name: _____ | PRESCRIBER INFORMATION | Prescriber's Name: _____ |
| | Address: _____ | | State License #: _____ NPI #: _____ |
| | City: _____ State: _____ Zip: _____ | | DEA #: _____ |
| | Primary Phone: _____ DOB: _____ | | Group or Hospital: _____ |
| | Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female | | Address: _____ |
| | E-mail: _____ | | City, State Zip: _____ State: _____ Zip: _____ |
| | Primary Language: _____ | | Phone: _____ Fax: _____ |
| | Height: _____ Weight: _____ | | Contact Person: _____ Phone: _____ |

INSURANCE INFORMATION: PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)

| | | | |
|------------------|---|--|-------------------------------------|
| CLINICAL | Need By Date: _____ | Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Other: | |
| | Date of Diagnosis: _____ | <input type="checkbox"/> Clinically Isolated Syndrome <input type="checkbox"/> Relapsing-Remitting <input type="checkbox"/> Secondary Progressive <input type="checkbox"/> Primary Progressive | Number of Relapses Last Year: _____ |
| | Diagnosis: G35 Multiple Sclerosis <input type="checkbox"/> Other (ICD-10 Code): _____ | | |
| | Previous Disease-Modifying Therapy: _____ | | |
| | Current Medications: _____ | | |
| Allergies: _____ | | Is the patient new to therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No | |

| MEDICATION | DOSE/STRENGTH | DIRECTIONS | QUANTITY | REFILLS |
|----------------------------------|--|--|--|---------|
| <input type="checkbox"/> Zeposia | <input type="checkbox"/> Titration Pack (7-day) | <input type="checkbox"/> Titration Dose: 0.23mg PO day 1-4, 0.46mg day 5-7, followed by 0.92mg daily thereafter. | <input type="checkbox"/> 1 Titration Kit | NA |
| | <input type="checkbox"/> Titration Pack (37-day) | | | |
| | <input type="checkbox"/> 0.92mg cap | <input type="checkbox"/> Take 0.92mg PO daily. | <input type="checkbox"/> 30 | _____ |

PHYSICIAN SIGNATURE REQUIRED

x _____ x _____
 DISPENSE AS WRITTEN (Date) PRODUCT SUBSTITUTION PERMITTED (Date)
 Ancillary supplies and kits provided as needed for administration

Date Needed: _____ Medication Start Date: _____

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 0124 (7/20)

This prescription is valid only if transmitted by facsimile machine by a licensed provider.